10 Followers USX:REGN - Regeneron Pharmaceuticals Inc Regeneron Pharmaceuticals Inc
Sector: Health Care, Industry: Biotechnology
Next Earnings: 3 Nov 2021
Add to Watchlist
   
Add Alert 


Yahoo Finance (Live Price)

USD 652.0    +6.850 (+1.06%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

15 Sep 2021


Loading...
Loading...
Loading...

General

CEO: Dr. Leonard S. Schleifer

IPO: 1991-04-02

Headquarters: US

Employees: 9,635

Homepage

Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.